Identification

Name
Quinidine
Accession Number
DB00908  (APRD00136)
Type
Small Molecule
Groups
Approved, Investigational
Description

An optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular action potential, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.

Structure
Thumb
Synonyms
  • (+)-quinidine
  • (8R,9S)-Quinidine
  • (R)-(6-Methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol
  • (S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol
  • (S)-(6-Methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol
  • 6-methoxy-α-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol
  • beta-Quinine
  • Chinidin
  • Chinidinum
  • CIN-QUIN
  • Conchinin
  • Conquinine
  • Pitayine
  • Quinidina
  • α-(6-methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol
  • β-quinine
Product Ingredients
IngredientUNIICASInChI Key
Quinidine gluconateR6875N380F7054-25-3XHKUDCCTVQUHJQ-LCYSNFERSA-N
Quinidine hydrochlorideS4P5V5597B1668-99-1LBSFSRMTJJPTCW-VJAUXQICSA-N
Quinidine polygalacturonateH0C54E9D6827555-34-6Not applicable
Quinidine sulfateJ13S2394HE6591-63-5LOUPRKONTZGTKE-UYVJDWJCSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Quinidine Tab 200mgTablet200 mgOralApotex Corporation1979-12-312010-01-19Canada
Cardioquin TabletsTablet275 mgOralPurdue Pharma1961-12-312000-07-17Canada
Quinate Tab 325mgTablet325 mgOralRougier Pharma Division Of Ratiopharm Inc1979-12-312003-09-22Canada
Quinidex Extentabs Srt 300mgTablet, extended release300 mgOralWyeth Ayerst Canada Inc.1994-12-312001-10-29Canada
Quinidex Extentabs Srt 300mgTablet, extended release300 mgOralAyerst Laboratories1991-12-311996-09-10Canada
Quinidine 200 TabTablet200 mgOralPro Doc Limitee1982-12-312003-07-31Canada
Quinidine GluconateSolution80 mg/mLIntravenousEli Lilly & Co. Ltd.1950-07-12Not applicableUs
Quinidine Gluconate for Inj 80mg/ml USPLiquid80 mgIntramuscular; IntravenousEli Lilly & Co. Ltd.1991-12-311997-08-13Canada
Quinidine Sulfate 200mgTablet200 mgOralRougier Pharma Division Of Ratiopharm Inc1970-12-311999-09-27Canada
Quinidine Sulfate Injection 190mg/mlSolution190 mgIntramuscularHospira, Inc.1981-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-quin-G Tab 325mgTablet325 mgOralApotex Corporation1985-12-312010-01-19Canada
Novo-quinidin 200mgTablet200 mgOralNovopharm Limited1966-12-312005-08-10Canada
Quinidine GluconateTablet, extended release324 mg/1OralRichmond Pharmaceuticals1987-02-10Not applicableUs
Quinidine GluconateTablet, extended release324 mg/1OralCarilion Materials Management1987-02-10Not applicableUs53489 0141 05 nlmimage10 ba0e5d12
Quinidine GluconateTablet, extended release324 mg/1OralSun Pharmaceutical Industries Limited1987-02-10Not applicableUs
Quinidine SulfateTablet200 mg/1OralEon Labs, Inc.1976-11-24Not applicableUs
Quinidine SulfateTablet300 mg/1OralWatson Pharmaceuticals1981-06-09Not applicableUs
Quinidine SulfateTablet300 mg/1OralEon Labs, Inc.1983-09-26Not applicableUs
Quinidine SulfateTablet, film coated, extended release300 mg/1OralTeva1995-01-012016-03-31Us00093 9175 01 nlmimage10 b9355cea
Quinidine SulfateTablet200 mg/1OralCarilion Materials Management1976-11-24Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
NuedextaQuinidine sulfate (10 mg/1) + Dextromethorphan hydrobromide (20 mg/1)Capsule, gelatin coatedOralAvanir Pharmaceuticals2010-12-01Not applicableUs
International/Other Brands
Cardioquin / Kinidin / Quin-Release / Quinaglute / Quinalan / Quinicardine / Quinidex
Categories
UNII
ITX08688JL
CAS number
56-54-2
Weight
Average: 324.4168
Monoisotopic: 324.183778022
Chemical Formula
C20H24N2O2
InChI Key
LOUPRKONTZGTKE-LHHVKLHASA-N
InChI
InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1
IUPAC Name
(S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol
SMILES
[H][[email protected]@]12CCN(C[[email protected]@H]1C=C)[[email protected]]([H])(C2)[[email protected]@H](O)C1=C2C=C(OC)C=CC2=NC=C1

Pharmacology

Indication

For the treatment of ventricular pre-excitation and cardiac dysrhythmias

Structured Indications
Pharmacodynamics

Quinidine, a hydantoin anticonvulsant, is used alone or with phenobarbital or other anticonvulsants to manage tonic-clonic seizures, psychomotor seizures, neuropathic pain syndromes including diabetic neuropathy, digitalis-induced cardiac arrhythmias, and cardiac arrhythmias associated with QT-interval prolongation.

Mechanism of action

Quinidine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Quinidine may also act on the slow inward calcium current (ICa), the rapid (IKr) and slow (IKs) components of the delayed potassium rectifier current, the inward potassium rectifier current (IKI), the ATP-sensitive potassium channel (IKATP) and Ito.

TargetActionsOrganism
ASodium channel protein type 5 subunit alpha
inhibitor
Human
UPotassium channel subfamily K member 1
inhibitor
Human
UPotassium channel subfamily K member 6
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
  • 2 to 3 L/kg
  • 0.5 L/kg [congestive heart failure]
  • 3 to 5 L/kg [cirrhosis of the liver]
Protein binding

80-88%

Metabolism
Route of elimination

When the urine pH is less than 7, about 20% of administered quinidine appears unchanged in the urine, but this fraction drops to as little as 5% when the urine is more alkaline.

Half life

6-8 hours

Clearance
  • 3 – 5 mL/min/kg [adults]
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Quinidine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Quinidine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
2-HYDROXY-1,4-NAPHTHOQUINONEThe serum concentration of Quinidine can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe serum concentration of Quinidine can be increased when it is combined with 2-mercaptobenzothiazole.Vet Approved
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Quinidine.Experimental, Illicit
AbirateroneThe serum concentration of Quinidine can be increased when it is combined with Abiraterone.Approved
AcenocoumarolQuinidine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Quinidine.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Quinidine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Quinidine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Vet Approved
Acetyl sulfisoxazoleThe metabolism of Quinidine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Quinidine.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Quinidine.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Quinidine.Experimental
AclidiniumQuinidine may increase the anticholinergic activities of Aclidinium.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Quinidine.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Quinidine.Approved, Investigational
AlcuroniumQuinidine may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Quinidine is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Quinidine.Approved, Vet Approved
AlmasilateAlmasilate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Quinidine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Quinidine.Approved
AloglutamolAloglutamol may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Quinidine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Quinidine is combined with Alphaprodine.Illicit
AlprenololThe metabolism of Alprenolol can be decreased when combined with Quinidine.Approved, Withdrawn
AluminiumAluminium may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Quinidine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Quinidine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Quinidine.Approved
AmbenoniumThe therapeutic efficacy of Quinidine can be decreased when used in combination with Ambenonium.Approved
AmilorideThe therapeutic efficacy of Quinidine can be decreased when used in combination with Amiloride.Approved
AmineptineAmineptine may increase the QTc-prolonging activities of Quinidine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Quinidine.Approved, Withdrawn
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Quinidine.Approved
AmitriptylinoxideAmitriptylinoxide may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
AmlodipineThe serum concentration of Quinidine can be decreased when it is combined with Amlodipine.Approved
AmorolfineThe serum concentration of Quinidine can be increased when it is combined with Amorolfine.Approved, Investigational
AmoxapineAmoxapine may increase the QTc-prolonging activities of Quinidine.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Quinidine.Approved, Illicit, Investigational
Amphotericin BThe serum concentration of Quinidine can be increased when it is combined with Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Quinidine.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Quinidine.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Quinidine.Approved
AnidulafunginThe serum concentration of Quinidine can be increased when it is combined with Anidulafungin.Approved, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Quinidine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Quinidine.Approved, Investigational
ApalutamideThe serum concentration of Quinidine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
AprepitantThe serum concentration of Quinidine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Quinidine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Quinidine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Quinidine.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Quinidine can be increased when it is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Quinidine.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Quinidine.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Quinidine can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Quinidine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Quinidine is combined with Atorvastatin.Approved
AtracuriumQuinidine may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateQuinidine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Quinidine.Approved, Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Quinidine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Quinidine.Approved
Bafilomycin A1The serum concentration of Quinidine can be increased when it is combined with Bafilomycin A1.Experimental
BedaquilineBedaquiline may increase the QTc-prolonging activities of Quinidine.Approved
BenactyzineThe risk or severity of adverse effects can be increased when Quinidine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Quinidine.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Quinidine.Approved
Benzoic AcidThe serum concentration of Quinidine can be increased when it is combined with Benzoic Acid.Approved, Investigational
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Quinidine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Quinidine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Quinidine.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Quinidine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BifonazoleThe serum concentration of Quinidine can be increased when it is combined with Bifonazole.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Quinidine.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Quinidine.Approved
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Quinidine.Investigational
BoceprevirThe serum concentration of Quinidine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Quinidine.Experimental
BortezomibThe metabolism of Bortezomib can be decreased when combined with Quinidine.Approved, Investigational
BosentanThe serum concentration of Quinidine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Quinidine.Approved
Botulinum Toxin Type AQuinidine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BQuinidine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved, Investigational
Brefeldin AThe serum concentration of Quinidine can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinidine.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Quinidine.Approved, Investigational
BrinzolamideBrinzolamide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Quinidine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Quinidine.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Quinidine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Quinidine.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Quinidine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Quinidine.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Quinidine.Approved, Investigational
ButenafineThe serum concentration of Quinidine can be increased when it is combined with Butenafine.Approved
ButoconazoleThe serum concentration of Quinidine can be increased when it is combined with Butoconazole.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Quinidine is combined with Butorphanol.Approved, Illicit, Vet Approved
ButriptylineButriptyline may increase the QTc-prolonging activities of Quinidine.Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Quinidine is combined with Butylscopolamine.Approved, Investigational, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Quinidine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Quinidine.Approved
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
Calcium silicateCalcium silicate may decrease the excretion rate of Quinidine which could result in a higher serum level.Experimental
CandicidinThe serum concentration of Quinidine can be increased when it is combined with Candicidin.Withdrawn
CapecitabineThe metabolism of Quinidine can be decreased when combined with Capecitabine.Approved, Investigational
Capric acidThe serum concentration of Quinidine can be increased when it is combined with Capric acid.Experimental
CaptoprilThe metabolism of Captopril can be decreased when combined with Quinidine.Approved
CarbamazepineThe metabolism of Quinidine can be increased when combined with Carbamazepine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Quinidine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Quinidine.Approved, Investigational
CarteololThe metabolism of Carteolol can be decreased when combined with Quinidine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Quinidine.Approved, Investigational
CaspofunginThe serum concentration of Quinidine can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Quinidine can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Quinidine.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Quinidine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Quinidine.Approved, Withdrawn
CeruleninThe serum concentration of Quinidine can be increased when it is combined with Cerulenin.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Quinidine.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Quinidine.Approved, Illicit, Investigational
ChloroquineChloroquine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Quinidine.Approved, Vet Approved
ChloroxineThe serum concentration of Quinidine can be increased when it is combined with Chloroxine.Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Quinidine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Quinidine is combined with Chlorphenoxamine.Withdrawn
ChlorproethazineThe serum concentration of Chlorproethazine can be increased when it is combined with Quinidine.Experimental
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Quinidine.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Quinidine.Approved
CholecalciferolThe metabolism of Quinidine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Cholic AcidQuinidine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CiclopiroxThe serum concentration of Quinidine can be increased when it is combined with Ciclopirox.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Quinidine.Approved, Investigational
CimetidineThe serum concentration of Quinidine can be increased when it is combined with Cimetidine.Approved, Investigational
CimetropiumQuinidine may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Quinidine.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Quinidine.Approved, Investigational, Withdrawn
CisatracuriumQuinidine may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Quinidine.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Quinidine.Approved
ClemastineThe metabolism of Quinidine can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe serum concentration of Quinidine can be decreased when it is combined with Clevidipine.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Quinidine.Approved
ClorindioneQuinidine may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe serum concentration of Quinidine can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Quinidine.Approved
CobicistatThe serum concentration of Quinidine can be increased when it is combined with Cobicistat.Approved
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Quinidine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Quinidine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Quinidine.Approved, Investigational
CordycepinThe serum concentration of Quinidine can be increased when it is combined with Cordycepin.Investigational
CoumaphosThe therapeutic efficacy of Quinidine can be decreased when used in combination with Coumaphos.Vet Approved
CrisaboroleThe metabolism of Quinidine can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Quinidine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Quinidine.Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Quinidine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Quinidine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Quinidine.Approved, Investigational
CyclosporineThe serum concentration of Quinidine can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be increased when it is combined with Quinidine.Experimental
Cyproterone acetateThe serum concentration of Quinidine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Quinidine.Approved
DabrafenibThe serum concentration of Quinidine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalfampridineThe serum concentration of Dalfampridine can be increased when it is combined with Quinidine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Quinidine.Approved
DapsoneThe risk or severity of adverse effects can be increased when Quinidine is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Quinidine.Approved, Investigational
DarunavirThe serum concentration of Quinidine can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Quinidine can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Quinidine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Quinidine.Approved, Investigational
DecamethoniumQuinidine may increase the neuromuscular blocking activities of Decamethonium.Approved
DeferasiroxThe serum concentration of Quinidine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Quinidine.Approved
DelamanidQuinidine may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Quinidine.Approved
DemecariumThe therapeutic efficacy of Quinidine can be decreased when used in combination with Demecarium.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Quinidine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Quinidine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Quinidine is combined with Desloratadine.Approved, Investigational
DeutetrabenazineQuinidine may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Quinidine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Quinidine.Withdrawn
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Quinidine.Approved, Illicit, Investigational, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Quinidine.Approved, Investigational
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Quinidine.Approved, Illicit
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Quinidine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Quinidine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Quinidine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dezocine.Approved, Investigational
DibenzepinDibenzepin may increase the QTc-prolonging activities of Quinidine.Experimental
DichloropheneThe serum concentration of Quinidine can be increased when it is combined with Dichlorophene.Vet Approved
DichlorvosThe therapeutic efficacy of Quinidine can be decreased when used in combination with Dichlorvos.Vet Approved
DiclofenamideDiclofenamide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
DicoumarolQuinidine may increase the anticoagulant activities of Dicoumarol.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Quinidine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Quinidine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Quinidine.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Quinidine.Approved
DihydrocodeineQuinidine may decrease the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Quinidine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Quinidine.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Quinidine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Quinidine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe serum concentration of Quinidine can be increased when it is combined with Diltiazem.Approved, Investigational
DimetacrineDimetacrine may increase the QTc-prolonging activities of Quinidine.Approved, Withdrawn
DiphenadioneQuinidine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Quinidine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Quinidine is combined with Diphenoxylate.Approved, Illicit
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Quinidine.Approved
DistigmineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Distigmine.Experimental
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Quinidine.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
Domoic AcidQuinidine may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DomperidoneThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Quinidine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Quinidine.Approved
DorzolamideDorzolamide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
DosulepinDosulepin may increase the QTc-prolonging activities of Quinidine.Approved
Doxacurium chlorideQuinidine may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Quinidine.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Quinidine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Quinidine.Approved, Investigational
DoxycyclineThe metabolism of Quinidine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Quinidine is combined with DPDPE.Experimental
DronabinolQuinidine may increase the tachycardic activities of Dronabinol.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Quinidine.Approved, Vet Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Quinidine.Approved
EchothiophateThe therapeutic efficacy of Quinidine can be decreased when used in combination with Echothiophate.Approved
EconazoleThe serum concentration of Quinidine can be increased when it is combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Quinidine.Approved
EdrophoniumThe therapeutic efficacy of Quinidine can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe metabolism of Quinidine can be decreased when combined with Efavirenz.Approved, Investigational
EfinaconazoleThe serum concentration of Quinidine can be increased when it is combined with Efinaconazole.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Quinidine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Quinidine.Approved
EluxadolineQuinidine may increase the constipating activities of Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Quinidine is combined with Emepronium.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Quinidine.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Quinidine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Quinidine.Investigational
EnzalutamideThe serum concentration of Quinidine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Quinidine.Approved, Investigational
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Quinidine.Experimental
EplerenoneThe therapeutic efficacy of Quinidine can be decreased when used in combination with Eplerenone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Quinidine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Quinidine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Quinidine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Quinidine.Investigational
EtanautineThe risk or severity of adverse effects can be increased when Quinidine is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Quinidine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Quinidine which could result in a higher serum level.Withdrawn
Ethyl biscoumacetateQuinidine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Quinidine.Approved, Illicit
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Quinidine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Quinidine can be decreased when it is combined with Etravirine.Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Quinidine is combined with Etybenzatropine.Experimental
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Quinidine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Quinidine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Quinidine.Approved
FelodipineThe serum concentration of Quinidine can be decreased when it is combined with Felodipine.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Quinidine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Quinidine can be decreased when used in combination with Fenthion.Vet Approved
FenticonazoleThe serum concentration of Quinidine can be increased when it is combined with Fenticonazole.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quinidine.Approved
FingolimodFingolimod may increase the arrhythmogenic activities of Quinidine.Approved, Investigational
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Quinidine.Approved
FlecainideFlecainide may increase the QTc-prolonging activities of Quinidine.Approved, Withdrawn
FloxuridineThe metabolism of Quinidine can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Quinidine can be increased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe serum concentration of Quinidine can be increased when it is combined with Flucytosine.Approved, Investigational
FluindioneQuinidine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Quinidine.Approved
FluorouracilThe metabolism of Quinidine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Quinidine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Quinidine.Approved, Investigational, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Quinidine.Approved
FlutrimazoleThe serum concentration of Quinidine can be increased when it is combined with Flutrimazole.Experimental
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Quinidine.Approved
FluvoxamineThe serum concentration of Quinidine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Quinidine.Approved, Investigational
FosamprenavirThe serum concentration of Quinidine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Quinidine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Quinidine.Approved
FosphenytoinFosphenytoin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
Fusidic AcidThe serum concentration of Quinidine can be increased when it is combined with Fusidic Acid.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Quinidine.Approved
GallamineQuinidine may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideQuinidine may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GallopamilThe serum concentration of Quinidine can be increased when it is combined with Gallopamil.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Quinidine.Approved, Investigational
GemfibrozilThe metabolism of Quinidine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Quinidine.Experimental
Glucagon recombinantThe risk or severity of adverse effects can be increased when Quinidine is combined with Glucagon recombinant.Approved
GlycopyrroniumQuinidine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GlyphosateThe serum concentration of Quinidine can be increased when it is combined with Glyphosate.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Quinidine.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
GriseofulvinThe serum concentration of Quinidine can be increased when it is combined with Griseofulvin.Approved, Investigational, Vet Approved
HachimycinThe serum concentration of Quinidine can be increased when it is combined with Hachimycin.Experimental
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Quinidine.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Quinidine.Approved
HaloproginThe serum concentration of Quinidine can be increased when it is combined with Haloprogin.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Quinidine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Quinidine is combined with Heroin.Approved, Illicit, Investigational
HexetidineThe serum concentration of Quinidine can be increased when it is combined with Hexetidine.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Quinidine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Quinidine is combined with Homatropine.Approved
Human secretinThe therapeutic efficacy of Human secretin can be decreased when used in combination with Quinidine.Approved
Huperzine AThe therapeutic efficacy of Quinidine can be decreased when used in combination with Huperzine A.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Quinidine.Approved, Vet Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Quinidine resulting in a loss in efficacy.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Quinidine.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Quinidine.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Experimental, Investigational
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Quinidine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Quinidine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Quinidine.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Quinidine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Quinidine.Approved
IdelalisibThe metabolism of Quinidine can be decreased when combined with Idelalisib.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Quinidine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Quinidine.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Quinidine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Quinidine.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Quinidine.Approved
IndinavirThe serum concentration of Quinidine can be increased when it is combined with Indinavir.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Quinidine.Approved, Withdrawn
IpidacrineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Quinidine.Approved
IprindoleIprindole may increase the QTc-prolonging activities of Quinidine.Experimental
IrbesartanThe metabolism of Quinidine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Quinidine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Quinidine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe serum concentration of Quinidine can be increased when it is combined with Isoconazole.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Quinidine.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Quinidine can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Quinidine can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe serum concentration of Quinidine can be decreased when it is combined with Isradipine.Approved, Investigational
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Quinidine.Investigational
ItraconazoleThe serum concentration of Quinidine can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineQuinidine may increase the QTc-prolonging activities of Ivabradine.Approved
IvacaftorThe serum concentration of Quinidine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Quinidine.Approved, Investigational
KaolinThe serum concentration of Quinidine can be decreased when it is combined with Kaolin.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Quinidine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Quinidine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Quinidine.Approved
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Quinidine.Experimental
LapatinibLapatinib may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Quinidine.Approved
LeflunomideThe metabolism of Quinidine can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Quinidine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
LevodopaThe metabolism of Levodopa can be decreased when combined with Quinidine.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Quinidine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Quinidine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Quinidine is combined with Levorphanol.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Quinidine.Approved, Vet Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Quinidine.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Quinidine.Approved
LobeglitazoneThe metabolism of Quinidine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Quinidine is combined with Lofentanil.Illicit
LofepramineLofepramine may increase the QTc-prolonging activities of Quinidine.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Quinidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Quinidine.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Quinidine.Approved
LopinavirLopinavir may increase the QTc-prolonging activities of Quinidine.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Quinidine.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Quinidine.Approved
LorpiprazoleThe serum concentration of Quinidine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Quinidine can be decreased when combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Quinidine.Approved, Investigational
LuliconazoleThe serum concentration of Quinidine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Quinidine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Lumefantrine.Approved
LurasidoneLurasidone may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Quinidine.Illicit, Investigational, Withdrawn
MacimorelinQuinidine may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
MagaldrateMagaldrate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Withdrawn
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
Magnesium oxideMagnesium oxide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Quinidine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
MalathionThe therapeutic efficacy of Quinidine can be decreased when used in combination with Malathion.Approved, Investigational
ManidipineThe metabolism of Quinidine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Quinidine.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Quinidine is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quinidine.Approved, Investigational
MefloquineThe risk or severity of adverse effects can be increased when Quinidine is combined with Mefloquine.Approved, Investigational
MelitracenMelitracen may increase the QTc-prolonging activities of Quinidine.Experimental, Investigational
MemantineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Memantine.Approved, Investigational
MepartricinThe serum concentration of Quinidine can be increased when it is combined with Mepartricin.Experimental
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Quinidine.Investigational, Withdrawn
MeptazinolThe risk or severity of adverse effects can be increased when Quinidine is combined with Meptazinol.Experimental
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Quinidine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Quinidine.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Quinidine.Experimental
MethadoneMethadone may increase the QTc-prolonging activities of Quinidine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Quinidine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Quinidine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Quinidine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Quinidine is combined with Methantheline.Approved, Investigational
MethazolamideMethazolamide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Quinidine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Quinidine.Approved, Investigational, Vet Approved
MethscopolamineThe risk or severity of adverse effects can be increased when Quinidine is combined with Methscopolamine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Quinidine.Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Quinidine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Quinidine.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Quinidine.Approved, Investigational
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Quinidine is combined with Methylscopolamine bromide.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Quinidine.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Quinidine.Approved
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Quinidine.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Quinidine is combined with Metixene.Approved
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Quinidine.Approved, Investigational
MetocurineQuinidine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideQuinidine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Quinidine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Quinidine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Quinidine.Approved
MevastatinThe serum concentration of Quinidine can be increased when it is combined with Mevastatin.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Quinidine.Approved, Investigational
MianserinMianserin may increase the anticholinergic activities of Quinidine.Approved, Investigational
MicafunginThe serum concentration of Quinidine can be increased when it is combined with Micafungin.Approved, Investigational
MiconazoleThe serum concentration of Quinidine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Quinidine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
MiltefosineThe serum concentration of Quinidine can be increased when it is combined with Miltefosine.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Quinidine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Quinidine is combined with Mirabegron.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Quinidine.Approved
MitotaneThe serum concentration of Quinidine can be decreased when it is combined with Mitotane.Approved
MivacuriumQuinidine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Quinidine.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Quinidine.Approved
MonensinThe serum concentration of Quinidine can be increased when it is combined with Monensin.Vet Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Quinidine.Approved, Investigational, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Quinidine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
MyxothiazolThe serum concentration of Quinidine can be increased when it is combined with Myxothiazol.Experimental
NabiloneQuinidine may increase the tachycardic activities of Nabilone.Approved, Investigational
NaftifineThe serum concentration of Quinidine can be increased when it is combined with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Quinidine.Approved
NatamycinThe serum concentration of Quinidine can be increased when it is combined with Natamycin.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Quinidine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Quinidine.Approved, Investigational
NefazodoneThe metabolism of Quinidine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Quinidine can be increased when it is combined with Nelfinavir.Approved
NeosaxitoxinQuinidine may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NeostigmineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Quinidine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Quinidine can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Quinidine can be decreased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Quinidine.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Quinidine is combined with Nicomorphine.Experimental
NicotineThe metabolism of Nicotine can be decreased when combined with Quinidine.Approved
NifedipineThe serum concentration of Quinidine can be decreased when it is combined with Nifedipine.Approved
NifuratelThe serum concentration of Quinidine can be increased when it is combined with Nifuratel.Experimental
Nikkomycin ZThe serum concentration of Quinidine can be increased when it is combined with Nikkomycin Z.Investigational
NilotinibThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Quinidine can be decreased when it is combined with Nimodipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Quinidine.Approved
NisoldipineThe serum concentration of Quinidine can be decreased when it is combined with Nisoldipine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Quinidine.Approved, Investigational, Vet Approved
NitroxolineThe serum concentration of Quinidine can be increased when it is combined with Nitroxoline.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Quinidine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Quinidine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Quinidine.Approved
NystatinThe serum concentration of Quinidine can be increased when it is combined with Nystatin.Approved, Vet Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Quinidine.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Quinidine.Approved, Investigational
OlaparibThe metabolism of Quinidine can be decreased when combined with Olaparib.Approved
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Quinidine.Experimental, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Quinidine.Approved
OmbitasvirThe serum concentration of Quinidine can be increased when it is combined with Ombitasvir.Approved, Investigational
OmeprazoleThe metabolism of Quinidine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe serum concentration of Quinidine can be increased when it is combined with Omoconazole.Experimental
OndansetronOndansetron may increase the QTc-prolonging activities of Quinidine.Approved
OpipramolOpipramol may increase the QTc-prolonging activities of Quinidine.Investigational
OpiumThe metabolism of Opium can be decreased when combined with Quinidine.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Quinidine is combined with Orphenadrine.Approved
OsimertinibThe serum concentration of Quinidine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Quinidine is combined with Otilonium.Experimental, Investigational
OuabainThe serum concentration of Ouabain can be increased when it is combined with Quinidine.Approved
OxiconazoleThe serum concentration of Quinidine can be increased when it is combined with Oxiconazole.Approved
OxitropiumThe risk or severity of adverse effects can be increased when Quinidine is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Quinidine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Quinidine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Quinidine.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Quinidine.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Quinidine.Approved, Vet Approved
PafuramidineThe serum concentration of Quinidine can be increased when it is combined with Pafuramidine.Investigational
PalbociclibThe serum concentration of Quinidine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Quinidine.Approved, Investigational
PancuroniumQuinidine may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
ParaoxonThe therapeutic efficacy of Quinidine can be decreased when used in combination with Paraoxon.Experimental
ParitaprevirThe serum concentration of Quinidine can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Quinidine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Quinidine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Quinidine.Approved
PentamidineThe serum concentration of Quinidine can be increased when it is combined with Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Quinidine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Quinidine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Quinidine is combined with Pentolinium.Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Quinidine.Approved, Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Quinidine.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Quinidine.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Quinidine.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Quinidine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Quinidine.Approved
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Quinidine.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Quinidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Quinidine.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Quinidine is combined with Phenazocine.Experimental
PhenforminThe metabolism of Phenformin can be decreased when combined with Quinidine.Approved, Investigational, Withdrawn
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Quinidine.Experimental
PhenindioneQuinidine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalPhenobarbital may increase the hepatotoxic activities of Quinidine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Phenoperidine.Experimental
PhenprocoumonQuinidine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe serum concentration of Quinidine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Physostigmine.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Quinidine.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Quinidine.Approved, Investigational
PioglitazoneThe metabolism of Quinidine can be decreased when combined with Pioglitazone.Approved, Investigational
PipecuroniumQuinidine may increase the neuromuscular blocking activities of Pipecuronium.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Quinidine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Quinidine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Quinidine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Quinidine is combined with Piritramide.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Quinidine.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Quinidine.Approved, Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Quinidine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Quinidine.Approved, Investigational
PosaconazoleThe serum concentration of Quinidine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium ChlorideQuinidine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Quinidine.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Quinidine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Quinidine.Approved
PrimidoneThe serum concentration of Quinidine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Quinidine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Quinidine.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Quinidine.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Quinidine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Quinidine.Approved, Investigational
PropafenonePropafenone may increase the arrhythmogenic activities of Quinidine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Quinidine.Approved
PropericiazineThe serum concentration of Propericiazine can be increased when it is combined with Quinidine.Approved, Investigational
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Quinidine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Quinidine is combined with Propiverine.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Quinidine.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Quinidine.Approved, Investigational
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Quinidine.Experimental
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Quinidine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Quinidine.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Quinidine.Approved
PyrantelQuinidine may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Pyridostigmine.Approved, Investigational
PyrimethamineThe metabolism of Quinidine can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyrrolnitrinThe serum concentration of Quinidine can be increased when it is combined with Pyrrolnitrin.Experimental
QuetiapineThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Quetiapine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Quinidine.Approved
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Quinidine.Approved
RabeprazoleThe metabolism of Quinidine can be decreased when combined with Rabeprazole.Approved, Investigational
RadicicolThe serum concentration of Quinidine can be increased when it is combined with Radicicol.Experimental
RamosetronQuinidine may increase the constipating activities of Ramosetron.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Quinidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Quinidine.Approved, Investigational
RapacuroniumQuinidine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilThe risk or severity of adverse effects can be increased when Quinidine is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Quinidine.Approved, Withdrawn
RepinotanThe metabolism of Repinotan can be decreased when combined with Quinidine.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quinidine.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Quinidine.Approved, Investigational
RifabutinThe serum concentration of Quinidine can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Quinidine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Quinidine can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Quinidine can be decreased when it is combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Quinidine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Quinidine.Approved, Investigational
RitonavirThe serum concentration of Quinidine can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RocuroniumQuinidine may increase the neuromuscular blocking activities of Rocuronium.Approved
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Quinidine.Approved
RosiglitazoneThe metabolism of Quinidine can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Quinidine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Quinidine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Quinidine.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Quinidine.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Quinidine.Approved, Vet Approved
Salicylhydroxamic AcidThe serum concentration of Quinidine can be increased when it is combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe serum concentration of Quinidine can be increased when it is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Quinidine.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
SarilumabThe therapeutic efficacy of Quinidine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Quinidine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Quinidine.Approved, Investigational
SecobarbitalThe metabolism of Quinidine can be increased when combined with Secobarbital.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Quinidine.Approved, Investigational
SertaconazoleThe serum concentration of Quinidine can be increased when it is combined with Sertaconazole.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Quinidine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Quinidine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Quinidine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Quinidine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Quinidine.Approved
SiltuximabThe serum concentration of Quinidine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Quinidine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Quinidine.Approved
SinefunginThe serum concentration of Quinidine can be increased when it is combined with Sinefungin.Experimental
SirolimusThe serum concentration of Quinidine can be increased when it is combined with Sirolimus.Approved, Investigational
Sodium bicarbonateSodium bicarbonate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Quinidine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Quinidine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Quinidine.Experimental
SpironolactoneThe therapeutic efficacy of Quinidine can be decreased when used in combination with Spironolactone.Approved
St. John's WortThe serum concentration of Quinidine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Quinidine can be increased when it is combined with Stiripentol.Approved
SuccinylcholineQuinidine may increase the neuromuscular blocking activities of Succinylcholine.Approved
SucralfateThe serum concentration of Quinidine can be decreased when it is combined with Sucralfate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Quinidine is combined with Sufentanil.Approved, Investigational
SulconazoleThe serum concentration of Quinidine can be increased when it is combined with Sulconazole.Approved
SulfadiazineThe metabolism of Quinidine can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Quinidine.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Quinidine.Approved, Vet Approved
SulpirideQuinidine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
TacrineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Quinidine.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Quinidine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Quinidine.Approved
TavaboroleThe serum concentration of Quinidine can be increased when it is combined with Tavaborole.Approved, Investigational
TegaserodThe metabolism of Tegaserod can be decreased when combined with Quinidine.Approved, Investigational, Withdrawn
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Quinidine.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Quinidine.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Quinidine.Approved
TerbinafineThe serum concentration of Quinidine can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Quinidine.Approved
TerconazoleThe serum concentration of Quinidine can be increased when it is combined with Terconazole.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Quinidine.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Quinidine.Experimental
TeriflunomideThe metabolism of Quinidine can be decreased when combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Quinidine.Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Quinidine.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Quinidine.Approved
ThiazinamThe serum concentration of Thiazinam can be increased when it is combined with Quinidine.Experimental
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Quinidine.Withdrawn
ThioproperazineThe serum concentration of Thioproperazine can be increased when it is combined with Quinidine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Quinidine.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Quinidine.Approved
ThymolThe serum concentration of Quinidine can be increased when it is combined with Thymol.Approved
TianeptineTianeptine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
TicagrelorThe metabolism of Quinidine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Quinidine.Approved
TilidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Tilidine.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Quinidine.Approved
TioclomarolQuinidine may increase the anticoagulant activities of Tioclomarol.Experimental
TioconazoleThe serum concentration of Quinidine can be increased when it is combined with Tioconazole.Approved
TiotropiumQuinidine may increase the anticholinergic activities of Tiotropium.Approved
TipranavirThe serum concentration of Quinidine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
TocilizumabThe serum concentration of Quinidine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Quinidine can be decreased when combined with Tolbutamide.Approved, Investigational
TolciclateThe serum concentration of Quinidine can be increased when it is combined with Tolciclate.Experimental
TolnaftateThe serum concentration of Quinidine can be increased when it is combined with Tolnaftate.Approved, Investigational, Vet Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Quinidine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Quinidine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Quinidine is combined with Topiramate.Approved
TopiroxostatThe metabolism of Quinidine can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Quinidine.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Quinidine.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Quinidine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Quinidine.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Quinidine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
TriamtereneThe therapeutic efficacy of Quinidine can be decreased when used in combination with Triamterene.Approved
TrichlorfonThe therapeutic efficacy of Quinidine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Quinidine.Approved, Vet Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Quinidine.Approved, Investigational
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Quinidine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Quinidine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Quinidine is combined with Trimethaphan.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Quinidine.Approved, Vet Approved
TrimetrexateThe serum concentration of Quinidine can be increased when it is combined with Trimetrexate.Approved, Investigational
TrimipramineTrimipramine may increase the QTc-prolonging activities of Quinidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Quinidine.Approved, Vet Approved
TromethamineTromethamine may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
TropatepineThe risk or severity of adverse effects can be increased when Quinidine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Quinidine.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Quinidine.Approved
TubocurarineQuinidine may increase the neuromuscular blocking activities of Tubocurarine.Approved
TyrothricinThe therapeutic efficacy of Quinidine can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumQuinidine may increase the anticholinergic activities of Umeclidinium.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Quinidine.Approved, Investigational
Valproic AcidThe metabolism of Quinidine can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Quinidine can be decreased when combined with Valsartan.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Quinidine.Approved
VecuroniumQuinidine may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Quinidine.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Quinidine.Approved
VerapamilThe risk or severity of hypotension can be increased when Quinidine is combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Quinidine.Approved, Investigational
VilanterolVilanterol may increase the QTc-prolonging activities of Quinidine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Quinidine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Quinidine.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Quinidine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Quinidine.Approved, Investigational
VoriconazoleThe serum concentration of Quinidine can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Quinidine.Approved, Investigational
WarfarinQuinidine may increase the anticoagulant activities of Warfarin.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Quinidine.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Quinidine can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Quinidine.Approved, Investigational
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Quinidine.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Quinidine.Approved
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Preferably take on an ampty stomach.

References

Synthesis Reference

Jean Paul REMON, Chris Vervaet, "QUININE AND QUINIDINE SALTS, METHODS FOR MAKING THEM, AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM." U.S. Patent US20090239900, issued September 24, 2009.

US20090239900
General References
Not Available
External Links
Human Metabolome Database
HMDB0015044
KEGG Drug
D08458
KEGG Compound
C06527
PubChem Compound
441074
PubChem Substance
46505356
ChemSpider
389880
BindingDB
50121975
ChEBI
28593
ChEMBL
CHEMBL1294
Therapeutic Targets Database
DAP000515
PharmGKB
PA451209
IUPHAR
2342
Guide to Pharmacology
GtP Drug Page
HET
QDN
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Quinidine
ATC Codes
C01BA01 — QuinidineC01BA51 — Quinidine, combinations excl. psycholepticsC01BA71 — Quinidine, combinations with psycholeptics
AHFS Codes
  • 24:04.00 — Cardiac Drugs
  • 24:04.04.04 — Class IA Antiarrythmics
PDB Entries
4wnu
FDA label
Download (615 KB)
MSDS
Download (73 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceDrug Induced Constipation1
1CompletedBasic ScienceHealthy Adult Male and Female Volunteers1
1CompletedTreatmentDrug-induced Surface ECG Changes1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1TerminatedTreatmentHealthy Volunteers1
2CompletedTreatmentAcute Agitation / Alzheimer's Disease (AD)1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAutism, Early Infantile1
2CompletedTreatmentCentral Neuropathic Pain / Disseminated Sclerosis1
2CompletedTreatmentDyskinesias / Parkinson's Disease (PD)1
2CompletedTreatmentEpisodic Migraine1
2CompletedTreatmentMajor Depressive Disorder (MDD) / Treatment Resistant1
2, 3RecruitingPreventionArrythmias1
3CompletedPreventionArrythmias / Cardiovascular Disease (CVD) / Heart Arrest / Heart Diseases / Myocardial Infarction (MI) / Severe ventricular arrhythmias1
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Death, Sudden,Cardiac / Heart Diseases / Severe ventricular arrhythmias / Ventricular Arrythmias / Ventricular Tachycardia (VT)1
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Heart Diseases / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentPseudobulbar Affect (PBA)1
4Active Not RecruitingSupportive CareAlzheimer's Disease (AD) / Pseudobulbar Affect (PBA)1
4TerminatedNot AvailablePseudobulbar Affect (Involuntary Laughing and/or Crying)1
4Unknown StatusTreatmentDementias / Pseudobulbar Affect (PBA) / Strokes / Traumatic Brain Injury (TBI)1

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
  • Warner chilcott div warner lambert co
  • Bayer healthcare pharmaceuticals inc
  • Lannett co inc
  • Watson laboratories inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Halsey drug co inc
  • Mutual pharmaceutical co inc
  • Roxane laboratories inc
  • Sandoz inc
  • Superpharm corp
  • Pharmaceutical research assoc inc
  • Solvay pharmaceuticals
  • Wyeth pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Barr laboratories inc
  • Clonmel healthcare ltd
  • Contract pharmacal corp
  • Elkins sinn div ah robins co inc
  • Everylife
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • King pharmaceuticals inc
  • Kv pharmaceutical co
  • Lederle laboratories div american cyanamid co
  • L perrigo co
  • Pharmavite pharmaceuticals
  • Purepac pharmaceutical co
  • Scherer laboratories inc
  • Usl pharma inc
  • Valeant pharmaceuticals international
  • Vangard laboratories inc div midway medical co
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Key pharmaceuticals inc sub schering plough corp
  • Schering corp
Packagers
  • Amend
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • Consolidated Midland Corp.
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Eli Lilly & Co.
  • Eon Labs
  • H and H Laboratories
  • Heartland Repack Services LLC
  • Kaiser Foundation Hospital
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Qualitest
  • Resource Optimization and Innovation LLC
  • Richmond Pharmacy
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral275 mg
Capsule, gelatin coatedOral
TabletOral325 mg
Tablet, extended releaseOral300 mg
SolutionIntravenous80 mg/mL
Tablet, extended releaseOral324 mg/1
LiquidIntramuscular; Intravenous80 mg
TabletOral200 mg/1
TabletOral300 mg/1
Tablet, film coated, extended releaseOral300 mg/1
SolutionIntramuscular190 mg
TabletOral195 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Quinidine gluc 80 mg/ml vial2.16USD ml
Quinidine sulfate crystals1.58USD g
QuiNIDine Gluconate CR 324 mg Controlled Release Tabs0.97USD tab
Quinidine gluc er 324 mg tab0.93USD each
Quinidine Sulfate 300 mg0.41USD tablet
Quinidine sulfate 300 mg tablet0.4USD tablet
Quinidine Sulfate 200 mg0.22USD tablet
Quinidine sulfate 200 mg tablet0.21USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7659282No2006-08-132026-08-13Us
US8227484No2003-07-172023-07-17Us
USRE38115No1996-01-262016-01-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)174 °CPhysProp
water solubility140 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.44HANSCH,C ET AL. (1995)
logS-3.37ADME Research, USCD
Caco2 permeability-4.69ADME Research, USCD
pKa8.56 (at 25 °C)SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.334 mg/mLALOGPS
logP2.82ALOGPS
logP2.51ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)13.89ChemAxon
pKa (Strongest Basic)9.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area45.59 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity94.69 m3·mol-1ChemAxon
Polarizability35.82 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9836
Blood Brain Barrier+0.9382
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor IInhibitor0.8208
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.762
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5754
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7225
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.972
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0596 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5884
hERG inhibition (predictor II)Inhibitor0.538
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (2.96 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0bt9-0908000000-f7ff24907014d8850472
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-08fr-0907000000-f6d31042d549da6bcfd0
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0bt9-0709000000-2c0e665e2c3031c8e517
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-00di-0009133000-a893d9e0e441c597fac3
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-00di-0009001000-0a0220fd8eeb9e62bc20
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0a4i-0469000000-3679f13f09481b3563c8
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0a4i-0459000000-60c4a39356a4afeef2d2
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0a4i-0239000000-644b48bb63dd87dac231
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0910000000-b0045fccdbe90e598912
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0229000000-f88b510f13aab6a2bb44
MS/MS Spectrum - , positiveLC-MS/MSsplash10-02ta-3900000000-46a157d2899290cbf4ab
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0200-2952000000-2777ab3374ec2b052b2e

Taxonomy

Description
This compound belongs to the class of organic compounds known as cinchona alkaloids. These are alkaloids structurally characterized by the presence of the cinchonan skeleton, which consists of a quinoline linked to an azabicyclo[2.2.2]octane moiety.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Cinchona alkaloids
Sub Class
Not Available
Direct Parent
Cinchona alkaloids
Alternative Parents
4-quinolinemethanols / Quinuclidines / Anisoles / Aralkylamines / Alkyl aryl ethers / Pyridines and derivatives / Piperidines / Heteroaromatic compounds / Trialkylamines / Secondary alcohols
show 5 more
Substituents
Cinchonan-skeleton / 4-quinolinemethanol / Quinoline / Anisole / Quinuclidine / Alkyl aryl ether / Aralkylamine / Piperidine / Pyridine / Benzenoid
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cinchona alkaloid (CHEBI:28593)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN5A
Uniprot ID
Q14524
Uniprot Name
Sodium channel protein type 5 subunit alpha
Molecular Weight
226937.475 Da
References
  1. Stokoe KS, Thomas G, Goddard CA, Colledge WH, Grace AA, Huang CL: Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3. J Physiol. 2007 Jan 1;578(Pt 1):69-84. Epub 2006 Oct 5. [PubMed:17023504]
  2. Itoh H, Shimizu M, Takata S, Mabuchi H, Imoto K: A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs. J Cardiovasc Electrophysiol. 2005 May;16(5):486-93. [PubMed:15877619]
  3. Grant AO: Electrophysiological basis and genetics of Brugada syndrome. J Cardiovasc Electrophysiol. 2005 Sep;16 Suppl 1:S3-7. [PubMed:16138883]
  4. Napolitano C, Priori SG: Brugada syndrome. Orphanet J Rare Dis. 2006 Sep 14;1:35. [PubMed:16972995]
  5. Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S, Ohe T, Shimizu W: Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm. 2007 Jun;4(6):695-700. Epub 2007 Feb 20. [PubMed:17556186]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Sheets MF, Fozzard HA, Lipkind GM, Hanck DA: Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc Med. 2010 Jan;20(1):16-21. doi: 10.1016/j.tcm.2010.03.002. [PubMed:20685573]
  8. Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. [PubMed:9476974]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium channel activity
Specific Function
Ion channel that contributes to passive transmembrane potassium transport and to the regulation of the resting membrane potential in brain astrocytes, but also in kidney and in other tissues (PubMe...
Gene Name
KCNK1
Uniprot ID
O00180
Uniprot Name
Potassium channel subfamily K member 1
Molecular Weight
38142.775 Da
References
  1. Lesage F, Guillemare E, Fink M, Duprat F, Lazdunski M, Romey G, Barhanin J: TWIK-1, a ubiquitous human weakly inward rectifying K+ channel with a novel structure. EMBO J. 1996 Mar 1;15(5):1004-11. [PubMed:8605869]
  2. Fink M, Duprat F, Lesage F, Reyes R, Romey G, Heurteaux C, Lazdunski M: Cloning, functional expression and brain localization of a novel unconventional outward rectifier K+ channel. EMBO J. 1996 Dec 16;15(24):6854-62. [PubMed:9003761]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Potassium ion leak channel activity
Specific Function
Exhibits outward rectification in a physiological K(+) gradient and mild inward rectification in symmetrical K(+) conditions.
Gene Name
KCNK6
Uniprot ID
Q9Y257
Uniprot Name
Potassium channel subfamily K member 6
Molecular Weight
33746.8 Da
References
  1. Patel AJ, Maingret F, Magnone V, Fosset M, Lazdunski M, Honore E: TWIK-2, an inactivating 2P domain K+ channel. J Biol Chem. 2000 Sep 15;275(37):28722-30. [PubMed:10887187]
  2. Guerard NC, Traebert M, Suter W, Dumotier BM: Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart. J Pharmacol Toxicol Methods. 2008 Jul-Aug;58(1):32-40. doi: 10.1016/j.vascn.2008.05.129. Epub 2008 Jun 8. [PubMed:18582585]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Po SS, Wang DW, Yang IC, Johnson JP Jr, Nie L, Bennett PB: Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol. 1999 Feb;33(2):181-5. [PubMed:10028924]
  2. Dong DL, Li Z, Wang HZ, Du ZM, Song WH, Yang BF: Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels. Basic Clin Pharmacol Toxicol. 2004 May;94(5):209-12. [PubMed:15125690]
  3. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, Hong K, Bauersfeld U, Gaita F, Borggrefe M: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. [PubMed:15673388]
  4. Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J: The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther. 2005 Mar;10(1):67-76. [PubMed:15821840]
  5. Lin C, Cvetanovic I, Ke X, Ranade V, Somberg J: A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels. Am J Ther. 2005 Jul-Aug;12(4):328-36. [PubMed:16041196]
  6. Guerard NC, Traebert M, Suter W, Dumotier BM: Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart. J Pharmacol Toxicol Methods. 2008 Jul-Aug;58(1):32-40. doi: 10.1016/j.vascn.2008.05.129. Epub 2008 Jun 8. [PubMed:18582585]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [PubMed:9570190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [PubMed:9570190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [PubMed:9570190]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Ludwig E, Schmid J, Beschke K, Ebner T: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8. [PubMed:10381752]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
3. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. van Montfoort JE, Hagenbuch B, Fattinger KE, Muller M, Groothuis GM, Meijer DK, Meier PJ: Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther. 1999 Oct;291(1):147-52. [PubMed:10490898]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Li JH, Xu JQ, Cao XM, Ni L, Li Y, Zhuang YY, Gong JB: Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine. Clin Chim Acta. 2002 Mar;317(1-2):85-92. [PubMed:11814462]
  2. McCollam PL, Crouch MA, Arnaud P: Caucasian versus African-American differences in orosomucoid: potential implications for therapy. Pharmacotherapy. 1998 May-Jun;18(3):620-6. [PubMed:9620113]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365]
  2. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595]
  3. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ: Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5. [PubMed:11408531]
  2. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755]
  3. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257]
  4. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
  5. Zhang L, Gorset W, Dresser MJ, Giacomini KM: The interaction of n-tetraalkylammonium compounds with a human organic cation transporter, hOCT1. J Pharmacol Exp Ther. 1999 Mar;288(3):1192-8. [PubMed:10027858]
  6. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364]
  7. Sinclair CJ, Chi KD, Subramanian V, Ward KL, Green RM: Functional expression of a high affinity mammalian hepatic choline/organic cation transporter. J Lipid Res. 2000 Nov;41(11):1841-8. [PubMed:11060354]
  8. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595]
  9. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712]
  10. Martel F, Vetter T, Russ H, Grundemann D, Azevedo I, Koepsell H, Schomig E: Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):320-6. [PubMed:8878062]
  11. Busch AE, Quester S, Ulzheimer JC, Gorboulev V, Akhoundova A, Waldegger S, Lang F, Koepsell H: Monoamine neurotransmitter transport mediated by the polyspecific cation transporter rOCT1. FEBS Lett. 1996 Oct 21;395(2-3):153-6. [PubMed:8898084]
  12. Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, Koepsell H: Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem. 1996 Dec 20;271(51):32599-604. [PubMed:8955087]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
  2. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. [PubMed:11160873]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137]
  2. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287]
  3. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  4. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945]
  5. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153]
  6. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  7. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369]
  8. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992 Nov;263(2):840-5. [PubMed:1359120]
  9. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363]
  10. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998 Jan 15;101(2):289-94. [PubMed:9435299]
  11. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  12. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272]
  13. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926]
  14. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690]
  15. Smith BJ, Doran AC, McLean S, Tingley FD 3rd, O'Neill BT, Kajiji SM: P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1252-9. [PubMed:11504828]
  16. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]
  17. Neuhoff S, Ungell AL, Zamora I, Artursson P: pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003 Aug;20(8):1141-8. [PubMed:12948010]
  18. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  19. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
  20. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation. 1999 Feb 2;99(4):552-7. [PubMed:9927403]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ: Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5. [PubMed:11408531]
  2. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612]
  3. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
  4. van Montfoort JE, Hagenbuch B, Fattinger KE, Muller M, Groothuis GM, Meijer DK, Meier PJ: Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther. 1999 Oct;291(1):147-52. [PubMed:10490898]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Nozawa T, Tamai I, Sai Y, Nezu J, Tsuji A: Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol. 2003 Jul;55(7):1013-20. [PubMed:12906759]

Drug created on June 13, 2005 07:24 / Updated on May 22, 2018 23:47